Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Aclaris Therapeutics, Inc. (ACRS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $10.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $10.53M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $5.66M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $2.50M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $911.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $10.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.66M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $911.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $263.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $372.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $944.00K 10-K · filed 2025-02-27 |
| 2024-09-30 | $3.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $16.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $24.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $14.00K 10-K · filed 2024-02-27 |
| 2023-09-30 | $3.32M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $5.55M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $4.31M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $9.42M 10-K · filed 2023-02-23 |
| 2022-09-30 | $9.35M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $7.78M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $11.40M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $7.76M 10-K · filed 2022-02-24 |
| 2021-09-30 | $10.52M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $10.09M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $18.09M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $1.42M 10-K · filed 2021-02-25 |
| 2020-09-30 | $330.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $79.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $21.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $148.00K 10-K · filed 2020-02-25 |
| 2019-09-30 | $29.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $345.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.85M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $2.40M 10-K · filed 2019-03-18 |
| 2018-09-30 | $6.79M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $10.72M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $8.07M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $13.41M 10-K · filed 2018-03-12 |
| 2017-09-30 | $12.67M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $12.04M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $11.92M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $9.51M 10-K · filed 2017-03-15 |
| 2016-09-30 | $7.71M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $3.56M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $3.19M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $3.80M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |